These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

633 related articles for article (PubMed ID: 33391277)

  • 1. Genetic Engineering of Natural Killer Cells for Enhanced Antitumor Function.
    Mantesso S; Geerts D; Spanholtz J; Kučerová L
    Front Immunol; 2020; 11():607131. PubMed ID: 33391277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Purinergic targeting enhances immunotherapy of CD73
    Wang J; Lupo KB; Chambers AM; Matosevic S
    J Immunother Cancer; 2018 Dec; 6(1):136. PubMed ID: 30514403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition-Resistant CARs for NK Cell Cancer Immunotherapy.
    Zhuang X; Long EO
    Trends Immunol; 2019 Dec; 40(12):1078-1081. PubMed ID: 31732285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Engineering NK Cells for CAR Therapy-Recent Advances in Gene Transfer Methodology.
    Schmidt P; Raftery MJ; Pecher G
    Front Immunol; 2020; 11():611163. PubMed ID: 33488617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CAR-NK Cells: From Natural Basis to Design for Kill.
    Khawar MB; Sun H
    Front Immunol; 2021; 12():707542. PubMed ID: 34970253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Viral and Nonviral Engineering of Natural Killer Cells as Emerging Adoptive Cancer Immunotherapies.
    Matosevic S
    J Immunol Res; 2018; 2018():4054815. PubMed ID: 30306093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer Immunotherapy Based on Natural Killer Cells: Current Progress and New Opportunities.
    Hu W; Wang G; Huang D; Sui M; Xu Y
    Front Immunol; 2019; 10():1205. PubMed ID: 31214177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor activity of genetically engineered NK-cells in non-hematological solid tumor: a comprehensive review.
    Dash CP; Sonowal D; Dhaka P; Yadav R; Chettri D; Satapathy BP; Sheoran P; Uttam V; Jain M; Jain A
    Front Immunol; 2024; 15():1390498. PubMed ID: 38694508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CAR-NK cell in cancer immunotherapy; A promising frontier.
    Marofi F; Abdul-Rasheed OF; Rahman HS; Budi HS; Jalil AT; Yumashev AV; Hassanzadeh A; Yazdanifar M; Motavalli R; Chartrand MS; Ahmadi M; Cid-Arreguid A; Jarahian M
    Cancer Sci; 2021 Sep; 112(9):3427-3436. PubMed ID: 34050690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Next generation natural killer cells for cancer immunotherapy: the promise of genetic engineering.
    Daher M; Rezvani K
    Curr Opin Immunol; 2018 Apr; 51():146-153. PubMed ID: 29605760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 2B4 costimulatory domain enhancing cytotoxic ability of anti-CD5 chimeric antigen receptor engineered natural killer cells against T cell malignancies.
    Xu Y; Liu Q; Zhong M; Wang Z; Chen Z; Zhang Y; Xing H; Tian Z; Tang K; Liao X; Rao Q; Wang M; Wang J
    J Hematol Oncol; 2019 May; 12(1):49. PubMed ID: 31097020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy.
    Yilmaz A; Cui H; Caligiuri MA; Yu J
    J Hematol Oncol; 2020 Dec; 13(1):168. PubMed ID: 33287875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
    Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CAR-NK cells: A promising cellular immunotherapy for cancer.
    Xie G; Dong H; Liang Y; Ham JD; Rizwan R; Chen J
    EBioMedicine; 2020 Sep; 59():102975. PubMed ID: 32853984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Off-the-shelf cell therapy with induced pluripotent stem cell-derived natural killer cells.
    Saetersmoen ML; Hammer Q; Valamehr B; Kaufman DS; Malmberg KJ
    Semin Immunopathol; 2019 Jan; 41(1):59-68. PubMed ID: 30361801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. iPSC-Derived Natural Killer Cell Therapies - Expansion and Targeting.
    Goldenson BH; Hor P; Kaufman DS
    Front Immunol; 2022; 13():841107. PubMed ID: 35185932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetically Engineered Natural Killer Cells as a Means for Adoptive Tumor Immunotherapy.
    Michen S; Temme A
    Crit Rev Immunol; 2016; 36(4):329-347. PubMed ID: 28322137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Engineering Natural Killer Cells for Cancer Immunotherapy.
    Rezvani K; Rouce R; Liu E; Shpall E
    Mol Ther; 2017 Aug; 25(8):1769-1781. PubMed ID: 28668320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adoptive Transfer of NKG2D CAR mRNA-Engineered Natural Killer Cells in Colorectal Cancer Patients.
    Xiao L; Cen D; Gan H; Sun Y; Huang N; Xiong H; Jin Q; Su L; Liu X; Wang K; Yan G; Dong T; Wu S; Zhou P; Zhang J; Liang W; Ren J; Teng Y; Chen C; Xu XH
    Mol Ther; 2019 Jun; 27(6):1114-1125. PubMed ID: 30962163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical Assessment of Suitable Natural Killer Cell Sources for Chimeric Antigen Receptor Natural Killer-Based "Off-the-Shelf" Acute Myeloid Leukemia Immunotherapies.
    Kloess S; Oberschmidt O; Dahlke J; Vu XK; Neudoerfl C; Kloos A; Gardlowski T; Matthies N; Heuser M; Meyer J; Sauer M; Falk C; Koehl U; Schambach A; Morgan MA
    Hum Gene Ther; 2019 Apr; 30(4):381-401. PubMed ID: 30734584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.